日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study

巴瑞替尼和其他生物/靶向合成DMARDs治疗早期低疾病活动度或缓解期类风湿关节炎患者的长期疗效:RA-BE-REAL研究的2年数据

Alten, Rieke; Östör, Andrew; Edwards, Christopher J; Smolen, Josef S; Haladyj, Ewa; Ng, Khai Jing; Ogwu, Samuel; Kaneko, Yuko

Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

更正:巴瑞替尼在风湿病和皮肤病适应症中对高危人群特殊关注事件的安全性:基于随机试验数据的分析

Taylor, Peter C; Bieber, Thomas; Alten, Rieke; Witte, Torsten; Galloway, James; Deberdt, Walter; Issa, Maher; Haladyj, Ewa; De La Torre, Inmaculada; Grond, Susanne; Wollenberg, Andreas

Damage Burden in Polish Patients with Antiphospholipid Syndrome Measured Using Damage Index for Antiphospholipid Syndrome (DIAPS)

使用抗磷脂综合征损伤指数 (DIAPS) 测量波兰抗磷脂综合征患者的损伤负担

Haladyj, Ewa; Stypinska, Barbara; Matusiewicz, Agata; Kunisz, Wojciech; Olesinska, Marzena; Paradowska-Gorycka, Agnieszka

Distribution of HLA-DRB1 Alleles in Patients With Antiphospholipid Syndrome and Their Association With Antiphospholipid Antibodies Presence and Damage Indexes

抗磷脂综合征患者HLA-DRB1等位基因的分布及其与抗磷脂抗体存在和损伤指数的关系

Haladyj, Ewa; Stypinska, Barbara; Matusiewicz, Agata; Olesinska, Marzena; Paradowska-Gorycka, Agnieszka

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

类风湿关节炎患者自述疼痛与疾病缓解或低疾病活动度之间的关联:来自 RA-BE-REAL 前瞻性观察研究的数据

Taylor, Peter C; Fakhouri, Walid; Ogwu, Samuel; Haladyj, Ewa; de la Torre, Inmaculada; Fautrel, Bruno; Alten, Rieke; Nash, Peter; Feist, Eugen

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study

巴瑞替尼治疗中重度类风湿性关节炎患者长达6.5年的疗效:一项长期研究的结果

Caporali, Roberto; Taylor, Peter C; Aletaha, Daniel; Sanmartí, Raimon; Takeuchi, Tsutomu; Mo, Daojun; Haladyj, Ewa; Bello, Natalia; Zaremba-Pechmann, Liliana; Fang, Ying; Dougados, Maxime

Health-related quality of life impairment is equal for antiphospholipid syndrome whether primary or associated with systemic lupus erythematosus

无论抗磷脂综合征是原发性的还是与系统性红斑狼疮相关的,其健康相关的生活质量损害程度都相同。

Haladyj, Ewa; Matusiewicz, Agata; Wysocki, Tomasz; Olesinska, Marzena

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

巴瑞替尼在风湿病和皮肤病适应症中对高危人群特殊关注事件的安全性分析:来自随机试验数据的分析

Taylor, Peter C; Bieber, Thomas; Alten, Rieke; Witte, Torsten; Galloway, James; Deberdt, Walter; Issa, Maher; Haladyj, Ewa; De La Torre, Inmaculada; Grond, Susanne; Wollenberg, Andreas

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

更正:巴瑞替尼在风湿病、皮肤病和 COVID-19 临床试验中的安全性结果回顾

Bieber, Thomas; Feist, Eugen; Irvine, Alan D; Harigai, Masayoshi; Haladyj, Ewa; Ball, Susan; Deberdt, Walter; Issa, Maher; Grond, Susanne; Taylor, Peter C

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

用于治疗类风湿性关节炎的JAK抑制剂:巴瑞替尼的经验

Taylor, Peter C; Laedermann, Cedric; Alten, Rieke; Feist, Eugen; Choy, Ernest; Haladyj, Ewa; De La Torre, Inmaculada; Richette, Pascal; Finckh, Axel; Tanaka, Yoshiya